Browse by Journal Title

Article

Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients.
Panagiota, V. and Kerschbaum, J.F. and Penack, O. and Stein, C.M. and Arends, C.M. and Koenecke, C. and Strzelecka, P.M. and Kloos, A. and Wiegand, L. and Lasch, A. and Altwasser, R. and Halik, A. and Gabdoulline, R. and Thomson, J. and Weibl, K. and Franke, G.N. and Berger, C. and Hasenkamp, J. and Ayuk, F. and Na, I.K. and Beutel, G. and Keller, U. and Bullinger, L. and Wulf, G.G. and Kröger, N. and Vucinic, V. and Heuser, M. and Damm, F.
HemaSphere 7 (10): e957. October 2023

Inferior outcomes of EU versus US patients treated with CD19 CAR-T for relapsed/refractory large B-cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use.
Bücklein, V. and Perez, A. and Rejeski, K. and Iacoboni, G. and Jurinovic, V. and Holtick, U. and Penack, O. and Kharboutli, S. and Blumenberg, V. and Ackermann, J. and Frölich, L. and Johnson, G. and Patel, K. and Arciola, B. and Mhaskar, R. and Wood, A. and Schmidt, C. and Albanyan, O. and Gödel, P. and Hoster, E. and Bullinger, L. and Mackensen, A. and Locke, F. and von Bergwelt, M. and Barba, P. and Subklewe, M. and Jain, M.D.
HemaSphere 7 (8): e907. August 2023

The mTOR inhibitor temsirolimus added to rituximab combined with dexamethasone, cytarabine, and cisplatinum (R-DHAP) for the treatment of patients with relapsed or refractory DLBCL - results from the phase-II STORM trial.
Witzens-Harig, M. and Viardot, A. and Keller, U. and Wosniok, J. and Deuster, O. and Klemmer, J. and Geueke, A.M. and Meißner, J. and Ho, A.D. and Atta, J. and Marks, R. and La Rosée, P. and Buske, C. and Dreyling, M.H. and Hess, G.
HemaSphere 5 (10): e636. October 2021

Final results of a phase I/II trial of the combination Bendamustine and Rituximab with Temsirolimus (BeRT) in relapsed mantle cell lymphoma and follicular lymphoma.
Hess, G. and Wagner, K. and Keller, U. and La Rosee, P. and Atta, J. and Hübel, K. and Lerchenmueller, C. and Schoendube, D. and Witzens-Harig, M. and Ruckes, C. and Medler, C. and van Oordt, C. and Klapper, W. and Theobald, M. and Dreyling, M.
HemaSphere 4 (3): e398. June 2020

Review

The EHA Research Roadmap: Malignant Myeloid Diseases.
Döhner, H. and Malcovati, L. and Ossenkoppele, G.J. and Hochhaus, A. and Maria Vannucchi, A. and Bullinger, L. and Cervantes, F. and Craddock, C. and de Witte, T. and Döhner, K. and Dombret, H. and Fenaux, P. and Geissler, J. and Germing, U. and Guilhot, F. and Harrison, C. and Hellström-Lindberg, E. and Passamonti, F. and Sierra, J. and Skoda, R. and Wierzbowska, A.
HemaSphere 5 (9): e635. September 2021

Letter

Genotype and intensive pretreatment influence outcome of acute myeloid leukemia patients treated with venetoclax in combination with hypomethylating agents or low-dose cytarabine: "real world" data from germany.
Braitsch, K. and Schmalbrock, L.K. and Jung, P. and Bumeder, I. and Kiewe, P. and Hecker, J.S. and Verbeek, M. and Westermann, J. and Bullinger, L. and Keller, U. and Bassermann, F. and Krönke, J. and Götze, K.S. and Rieger, K.
HemaSphere 6 (9): e759. September 2022

Gene expression profiling predicts sensitivity of chronic lymphocytic leukemia cells to dasatinib.
Blätte, T.J. and Machnicki, M.M. and Glodkowska-Mrowka, E. and Dolnik, A. and Karp, M. and Karczmarczyk, A. and Giannopoulos, K. and Bullinger, L. and Stoklosa, T.
HemaSphere 5 (1): e514. January 2021

Editorial

NEMHESYS - European perspective on the implementation of next-generation sequencing into clinical diagnostics.
Serramito-Gómez, I. and Clarke, K.M. and Rodríguez-Vicente, A.E. and McGimpsey, J.E. and Abáigar, M. and Díez, C.B. and Benito, R. and Bullinger, L. and Mills, K.I. and Hernández Rivas, J.M.
HemaSphere 5 (3): e541. March 2021